Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | The emerging role of immunotherapy in early HR+ cancer

Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, discusses the potential role of immunotherapy in combination with chemotherapy for patients with luminal type breast cancer, highlighting the results of the KEYNOTE-756 (NCT03725059) and CheckMate 7FL (NCT04109066) trials, which showed an increase in pathologic complete response (pCR) rates with the addition of immune checkpoint inhibitors. While these results are promising, overall survival data are still pending, and it is likely that patient selection, including factors such as ER expression, PD-L1 status, and other biomarkers like MammaPrint, will be crucial in identifying those who may benefit from immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Okay, so today I’d like to discuss who needs chemotherapy with immunotherapy actually in the luminal type breast cancer. In general, luminal type breast cancer nowadays is treated by upfront surgery and doing chemotherapy after that. But for doing immunotherapeutic checkpoint inhibitor, we need to do a neoadjuvant therapy with immunochemotherapy. Today, there are two completed phase 3 studies, which are CheckMate 7FL and KEYNOTE-522...

Okay, so today I’d like to discuss who needs chemotherapy with immunotherapy actually in the luminal type breast cancer. In general, luminal type breast cancer nowadays is treated by upfront surgery and doing chemotherapy after that. But for doing immunotherapeutic checkpoint inhibitor, we need to do a neoadjuvant therapy with immunochemotherapy. Today, there are two completed phase 3 studies, which are CheckMate 7FL and KEYNOTE-522. And both have a pCR increase by adding immunotherapeutic checkpoint inhibitor. In KEYNOTE-756, it increased 8.5%. And in the KEYNOTE-522 study, it increased about 10% by adding immunotherapeutic checkpoint inhibitor. But we don’t have yet the result of eventual survival. So at this moment, we don’t have any chance of using our ICI in the early breast cancer setting, but probably we need to titrate the patient who has more benefit from immune checkpoint inhibitor, that is ER low expression or PD-L1 positive, and there are other kinds of margin assays which are MammaPrint or MP2 or Oncotype DX positive tumor. So this kind of more titrated patient may have a benefit by PD-1 inhibitor, but it’s not established yet.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.